Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carmustine + cisplatin + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of three alkylating agents—carmustine (BCNU), cisplatin (CDDP), and cyclophosphamide (CTX). The regimen is used as high-dose chemotherapy primarily in the treatment of certain cancers such as primary breast cancer and relapsed or refractory Hodgkin's disease. It is often administered prior to autologous stem cell transplantation or bone marrow transplantation. Each component acts by damaging DNA and inhibiting cancer cell replication through different mechanisms. Carmustine and cyclophosphamide are both alkylating agents that form cross-links in DNA, while cisplatin forms platinum-DNA adducts leading to apoptosis. This combination aims to maximize cytotoxicity against tumor cells with non-overlapping toxicities.
- Other names
- carmustine/cisplatin/cyclophosphamideBCNU/CDDP/CTXSTAMP I
02
Targets
DNA
Beyond the preview
Go deeper on carmustine + cisplatin + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carmustine + cisplatin + cyclophosphamide.